BillionToOne (BLLN)

Executive Summary

BillionToOne is a publicly traded precision diagnostics company (ticker: BLLN) that has commercialized two proprietary testing suites built on its single-molecule next-generation sequencing (smNGS) platform. The UNITY suite delivers non-invasive prenatal testing (NIPT) with industry-leading sensitivity, while the Northstar suite offers pan-cancer liquid biopsy for early detection across multiple tumor types. Since its IPO, BillionToOne has focused on expanding its clinical evidence base and reimbursement coverage. With over 25 publications and a growing commercial footprint, the company is positioned to capture share in the NIPT and liquid biopsy markets, which are each expected to exceed $5 billion globally. The company's smNGS technology differentiates it by enabling detection of disease-causing DNA at unprecedented 0.1% sensitivity, addressing unmet needs in oncology and prenatal care. Revenue growth is driven by test volume expansion and potential future FDA approvals.

Upcoming Catalysts (preview)

• Q3 2026FDA de novo clearance for Northstar pan-cancer liquid biopsy test40% success
• Q4 2026Publication of large-cohort validation study for UNITY NIPT in high-risk pregnancies60% success
• Q2 2026Strategic partnership with a top 10 pharma company for co-development of smNGS-based companion diagnostics30% success